Ge Healthcare patents expiration
1. Myoview 30ml patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549999 | GE HEALTHCARE | Radiopharmaceutical composition |
Mar, 2030
(5 years from now) | |
Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient
Market Authorisation Date: 09 February, 1996
Treatment: NA
Dosage: INJECTABLE;INJECTION
MYOVIEW 30ML family patents
2. Omniscan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5560903 | GE HEALTHCARE | Method of enhancing paramagnetism in chelates for MRI |
Oct, 2013
(10 years ago) | |
Drugs and Companies using GADODIAMIDE ingredient
Market Authorisation Date: 05 September, 2007
Treatment: NA
Dosage: INJECTABLE;INJECTION
OMNISCAN family patents
3. Optison patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5529766 | GE HEALTHCARE | Contrast agents |
Jun, 2013
(10 years ago) | |
| US6723303 | GE HEALTHCARE | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
Apr, 2021
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-120) | Aug 17, 2015 |
Drugs and Companies using ALBUMIN HUMAN ingredient
Market Authorisation Date: 31 December, 1997
Treatment: Ultrasound contrast agent
Dosage: INJECTABLE;INJECTION
OPTISON family patents
4. Vizamyl patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7351401 | GE HEALTHCARE | Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition |
Jan, 2023
(1 year, 3 months ago) | |
| US8236282 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
May, 2024
(23 days from now) | |
| US7270800 | GE HEALTHCARE | Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
Sep, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8691185 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
Jan, 2023
(1 year, 3 months ago) | |
| US8916131 | GE HEALTHCARE | Radiopharmaceutical composition |
Sep, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2018 |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
NCE-1 date: 25 October, 2017
Market Authorisation Date: 25 October, 2013
Treatment: Diagnostic radioimaging
Dosage: INJECTABLE;INTRAVENOUS
VIZAMYL family patents